Navigation Links
Pathwork Diagnostics Announces Key Additions to Management Team
Date:10/8/2008

CFO and VP of US Sales Bring Industry Expertise to Pathwork Following FDA

Clearance and $20M Fundraising Round

SUNNYVALE, Calif., Oct. 8 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, announced today the appointment of two key positions within the company's management team, Fletcher Payne as Chief Financial Officer and Mark McDonough as Vice President of US Sales. These professionals bring over 20 years of industry expertise in their respective positions to Pathwork.

"Having Fletcher and Mark on the Pathwork management team will be a great asset moving forward," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "Both have proven track records in helping emerging companies grow efficiently and achieve results."

Pathwork's new CFO, Fletcher Payne, a graduate of UC Berkeley's Haas School of Business with a BS in Business Administration, joins Pathwork from Plexxikon Inc., a biopharmaceutical company where he served as a VP and CFO. Payne will lead the financial team, implement processes to support commercial growth and develop the overall financial strategy. Payne has over 20 years of business and financial experience, in both start-up and Fortune 500 companies. Prior to Plexxikon, he worked for Rinat Neuroscience, Dynavax Technologies, Cell Genesys, Sun Microsystems and IBM.

Mark McDonough joins Pathwork as Vice President of US Sales from US LABS, a division of Laboratory Corporation of America. With over 10 years of cancer diagnostics and reference laboratory experience, Mark will be responsible for the strategic and tactical sales initiatives at Pathwork. Prior to his time at US LABS, McDonough held various sales and sales management roles at Ventana Medical Systems and served as a Navigator and Communications Officer in the United States Navy. McDonough is a graduate of Miami University of Ohio with a BS in Finance.

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Sunnyvale, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market -- the Pathwork(R) Tissue of Origin Test -- utilizes proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. The test aids in determining a hard-to-identify tumor's origin so that standard-of-care, cancer-specific treatment can begin. The test is FDA-cleared as an in vitro diagnostic kit, while a functionally equivalent version of the test is also available through the CLIA-certified Pathwork(R) Diagnostics Laboratory. For more information, call 1.877.808.0006 or visit http://www.pathworkdx.com.

Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics logo are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.


'/>"/>
SOURCE Pathwork Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pathwork Diagnostics Closes $20M Financing
2. Pathwork(R) Diagnostics Launches Genomics-Based Test For Hard-To-Identify Tumors Through Its CLIA-Certified Laboratory
3. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
4. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
5. Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
6. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
7. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
8. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
9. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
10. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
11. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps ... and North America this May on the following dates: , ?    London, ... Taylor, Chairman of the Learning and Performance Institute will be the opening ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... supplier of Common Lisp (CL) development tools, and market leader for Semantic ... key performance enhancements now available within the most effective system for developing and ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced TĀ·rejĀ·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):